Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
06/2000
06/29/2000WO2000037025A2 Antibodies to truncated vegf-d and uses thereof
06/29/2000WO2000012726A3 Rationally designed heparinases derived from heparinase i and ii
06/29/2000WO2000012113A3 Method of modulating memory effector t-cells using a cd2-binding agent, and compositions
06/29/2000WO2000009112A3 Heterocyclic esters or amides for vision and memory disorders
06/29/2000WO2000002543A3 Antihypersensitive combination of valsartan and calcium channel blocker
06/29/2000WO1999064034A9 β2-ADRENERGIC RECEPTOR AGONISTS
06/29/2000CA2356159A1 Novel spla2 inhibitors
06/29/2000CA2355902A1 Sulfonamide hydroxamates
06/29/2000CA2355896A1 Antibodies to truncated vegf-d and uses thereof
06/29/2000CA2355874A1 .alpha.v.beta.6 integrin inhibitors
06/29/2000CA2355148A1 Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions
06/29/2000CA2354135A1 Group b streptococcus proteins, and their use
06/29/2000CA2333626A1 Method for prevention and treatment of cancer and other cell proliferative diseases with ultrasonics
06/29/2000CA2293177A1 Nanoemulsion based on ethoxylate fatty ethers or ethoxylate fatty esters, and its utilizations in cosmetics, dermatology and/or ophthalmology
06/28/2000EP1013338A1 Nanoemulsion based on fatty esters of phosphoric acid and uses thereof in the fields of cosmetics, dermatology, pharmaceuticals and/or ophthalmology
06/28/2000EP1012296A2 Mammalian thioredoxin
06/28/2000EP1012271A1 Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
06/28/2000EP1012154A2 Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof
06/28/2000EP1012137A1 Aromatic c 16?-c 20?-substituted tetrahydro prostaglandins useful as fp agonists
06/28/2000EP1011728A1 Prostaglandin product
06/28/2000EP1011725A1 HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
06/28/2000EP1011327A1 Treatment or prophylaxis of retinal pathology and spinal cord injury
06/28/2000EP0866719B1 Method for treating retinal ganglion cell injury using glial cell line-derived neurotrophic factor (gdnf) protein product
06/28/2000EP0706394A4 Method and composition for topical treatment of damaged tissue using histamine phosphate as active ingredient
06/28/2000CN1258219A Benzocycloheptathiophene compounds
06/28/2000CN1257726A Medicine for treating ophthalmopathy
06/28/2000CN1053830C Method for preparation of drug for curing cataract of livestock
06/28/2000CN1053807C Vitamin E drop
06/27/2000US6080845 Monoclonal antibody against utricular epithelium
06/27/2000US6080758 Analgesics, antiinflammatory agents; asthma; allergic rhinitis
06/27/2000US6080732 Use of sulodexide and of the medicines containing it in the treatment of the diabetic retinopathy
06/27/2000CA2198564C Method of reducing tissue damage associated with non-cardiac ischemia
06/22/2000WO2000036105A1 Prostacyclin-stimulating factor-2
06/22/2000WO2000036104A1 Pancreatic polypeptide zsig66
06/22/2000WO2000035939A2 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000WO2000035936A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000WO2000035915A1 Piperazine derivatives
06/22/2000WO2000035911A1 Heteroaryl-cyclic acetals
06/22/2000WO2000035907A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
06/22/2000WO2000035891A1 Morpholinone and morpholine derivatives and uses thereof
06/22/2000WO2000035864A1 New biphenyl and biphenyl-analogous compounds as integrin antagonists
06/22/2000WO2000035862A1 Amido polybiguanides and the use thereof as antimicrobial agents
06/22/2000WO2000035848A1 Aldose reductase inhibitors and pharmaceutical compositions
06/22/2000WO2000035477A2 Multi-component vaccine comprising at least two antigens from haemophilus influenzae
06/22/2000WO2000035452A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
06/22/2000WO2000035447A1 Use of riluzole for treating acoustic traumas
06/22/2000WO2000035444A1 USE OF η-TOCOPHEROL AND ITS OXIDATIVE METABOLITE LLU-α IN THE TREATMENT OF DISEASE
06/22/2000WO2000035432A2 Improved viscoelastic compositions and methods of use
06/22/2000WO2000035428A2 Tricyclic nitrogen heterocycles as pde iv inhibitors
06/22/2000WO2000015244A3 Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor
06/22/2000CA2355363A1 Prostacyclin-stimulating factor-2
06/22/2000CA2355211A1 Aldose reductase inhibitors and pharmaceutical compositions
06/22/2000CA2355202A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
06/22/2000CA2355201A1 Morpholinone and morpholine derivatives and uses thereof
06/22/2000CA2355161A1 Biphenyl and biphenyl-analogous compounds as integrin antagonists
06/22/2000CA2355039A1 Pancreatic polypeptide zsig66
06/22/2000CA2354875A1 Piperazine derivatives
06/22/2000CA2354456A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000CA2354422A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000CA2352079A1 Amido polybiguanides and the use thereof as antimicrobial agents
06/22/2000CA2347770A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
06/22/2000CA2345752A1 Tricyclic nitrogen heterocycles as pde iv inhibitors
06/21/2000EP1010431A2 Botulinum toxins for treating pain associated with muscle spasms
06/21/2000EP1009753A1 Hypoxia-regulated genes
06/21/2000EP1009738A1 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
06/21/2000EP1009737A2 Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
06/21/2000EP1009413A2 Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
06/21/2000EP1009409A1 Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate
06/21/2000EP1009388A1 Sustained release drug delivery devices
06/21/2000EP1009380A1 Method for preparing pharmaceutical formulations
06/21/2000DE19858331A1 Tricyclische Stickstoffheterocyclen als PDE IV Inhibitoren Tricyclic nitrogen heterocycles as PDE IV inhibitors
06/21/2000CN1257474A New nitromethyl ketones, process for preparing them and compositions containing them
06/21/2000CN1257431A Chemically and thermally stable norastemizole formulations
06/21/2000CN1257430A Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
06/21/2000CN1256945A External medicine for treating ophthalmia
06/20/2000US6077839 Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists
06/20/2000US6077829 Comprising brain derived neurotrophic factor(bdnf), polyoxyethylene sorbitan monooleate as nonionic surfactant, and carrier; prevents denaturing and polymerization of bdnf; storage stability
06/20/2000CA2198536C Method of reducing tissue damage associated with ischemia
06/15/2000WO2000034780A2 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3?
06/15/2000WO2000034498A1 Two-step immunization procedure against chlamydia infection
06/15/2000WO2000034474A2 Growth factor homolog zvegf3
06/15/2000WO2000034468A2 Muc-1 antagonists and methods of treating immune disorders
06/15/2000WO2000034258A2 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group
06/15/2000WO2000034254A1 Novel compounds
06/15/2000WO2000034248A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
06/15/2000WO2000033842A1 Myt1 kinase inhibitors
06/15/2000WO2000033841A1 Myt1 kinase inhibitors
06/15/2000WO2000033837A2 Myt1 kinase inhibitors
06/15/2000WO2000033834A1 Use of isatin derivatives as ion channel activating agents
06/15/2000WO2000033828A1 Agent for lowering endothelin levels
06/15/2000WO2000033814A2 Method for administering agents to the central nervous system
06/15/2000WO2000009107A3 Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders
06/15/2000WO2000006531A3 Nitric esters and nitrate salts of specific drugs
06/15/2000CA2354644A1 Muc-1 antagonists and methods of treating immune disorders
06/15/2000CA2351452A1 Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3
06/15/2000CA2350767A1 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group
06/15/2000CA2349616A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
06/14/2000EP1008347A1 Preventives or remedies for diseases affecting excessive proliferation of retinal pigment epithelial cells
06/14/2000EP1007645A1 Human serum inducible kinase (snk)
06/14/2000EP1007512A1 Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors
1 ... 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 ... 531